Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
R. Fonte(Istituto Tumori Bari), Amalia Azzariti(Istituto Tumori Bari)
Cited by 16
Related Papers
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
|Molecular Cancer|2022|147
Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin‐332/α3 integrin axis recovery of focal adhesion kinase ubiquitination
|Hepatology|2016|102
The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study
|Scientific Reports|2020|36
Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights
|Cancers|2021|24
A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents
|Toxicology in Vitro|2010|16